Phase II study of i.v. menogaril in patients with malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group Study.
D000328:Adult; D000368:Aged; D002170:Canada; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D017290:Menogaril; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009621:Nogalamycin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*
D017290:Menogaril; D009621:Nogalamycin; D003630:Daunorubicin